Education
About Us
Working with TipRanks
Follow Us
Rapport Therapeutics, Inc. (RAPP)
:RAPP
RAPP Stock Chart & Stats
$29.71
-$0.34(-1.94%)
At close: 4:00 PM EST
$29.71
-$0.34(-1.94%)
Day’s Range― - ―
52-Week Range$6.43 - $42.27
Previous CloseN/A
Volume10.11K
Average Volume (3M)373.83K
Market Cap
$1.42B
Enterprise Value$625.30M
Total Cash (Recent Filing)$513.03M
Total Debt (Recent Filing)$11.87M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Mar 17, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding47,661,137
10 Day Avg. Volume359,459
30 Day Avg. Volume373,835
Financial Highlights & Ratios
PEG Ratio-0.47
Price to Book (P/B)12.05
Price to Sales (P/S)0.00
P/FCF Ratio-54.72
Enterprise Value/Market Cap0.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.90
Forecast
1Y Price Target
$53.00Price Target Upside78.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.81
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyRAP-219 reduced long episodes by 71% and clinical seizures by 78% in an open-label study in focal epilepsy patients.
Market PotentialRAP-219 could achieve risk-adjusted net sales of $2.2B at peak market penetration in the U.S.
Safety ProfileThe safety of RAP-219 is very compelling for a drug of its potency, with no serious adverse events reported.
Bears Say
Adverse EffectsDr. Anschel expressed concern about the potential impacts of RAP-219 on memory as an adverse effect.
Drug CompetitionRAP-219 faces competition from other more advanced drugs in the space.
PharmacokineticsThe 8-14 day half-life of RAP-219 may be undesirable because of the time it takes to reach a steady state.
RAPP FAQ
What was Rapport Therapeutics, Inc.’s price range in the past 12 months?
Rapport Therapeutics, Inc. lowest stock price was $6.43 and its highest was $42.27 in the past 12 months.
What is Rapport Therapeutics, Inc.’s market cap?
Rapport Therapeutics, Inc.’s market cap is $1.42B.
When is Rapport Therapeutics, Inc.’s upcoming earnings report date?
Rapport Therapeutics, Inc.’s upcoming earnings report date is Mar 17, 2026 which is in 105 days.
How were Rapport Therapeutics, Inc.’s earnings last quarter?
Rapport Therapeutics, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.71 earnings per share for the quarter, beating the consensus estimate of -$0.775 by $0.065.
Is Rapport Therapeutics, Inc. overvalued?
According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued.
Does Rapport Therapeutics, Inc. pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
What is Rapport Therapeutics, Inc.’s EPS estimate?
Rapport Therapeutics, Inc.’s EPS estimate is -0.66.
How many shares outstanding does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. has 47,661,137 shares outstanding.
What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?
Rapport Therapeutics, Inc. reported an EPS of -$0.71 in its last earnings report, beating expectations of -$0.775. Following the earnings report the stock price went down -3.095%.
Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RAPP
Rapport Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.00 (78.39% Upside)
$53.00 (78.39% Upside)
Blogger Sentiment
Bullish
RAPP Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.69%
12-Months-Change
Fundamentals
Return on Equity
-23.41%
Trailing 12-Months
Asset Growth
61.66%
Trailing 12-Months
Company Description
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. (RAPP) is a biotechnology company focused on developing precision medicines to treat neurological disorders. By leveraging advanced drug discovery techniques, the company aims to create targeted therapies that address specific neural pathways associated with various conditions. Rapport Therapeutics operates in the biopharmaceutical sector, with a core emphasis on innovative research and development in neuroscience.
RAPP Stock 12 Month Forecast
Average Price Target
$53.00
▲(78.39% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---